High expression of MAGE-A4 and MHC class I antigens in tumor cells and induction of MAGE-A4 immune responses are prognostic markers of CHP-MAGE-A4 cancer vaccine

Vaccine

Volumn 32, Issue 45, 2014, Pages 5901-5907

  Saito, Takuro ^a   Wada, Hisashi ^a,b   Yamasaki, Makoto ^a   Miyata, Hiroshi ^a   Nishikawa, Hiroyoshi ^c   Sato, Eiichi ^d   Kageyama, Shinichi ^e   Shiku, Hiroshi ^e   Mori, Masaki ^a   Doki, Yuichiro ^a  

^a Department of Gastroenterological Surgery ^*  (Japan)

^b Graduate School of Biomedical Engineering   (Japan)

^c OSAKA UNIVERSITY   (Japan)

^d TOKYO MEDICAL UNIVERSITY   (Japan)

^e MIE UNIVERSITY   (Japan)

Author keywords

Cancer vaccine; CT antigen; MAGE A4; MHC; Monitoring; Prognosis

Indexed keywords

CANCER VACCINE; CHOLESTERYL PULLULAN MELANOMA ANTIGEN 4 VACCINE; GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NANOPARTICLE; PULLULAN; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; CANCER ANTIBODY; HLA ANTIGEN CLASS 1; IFNG PROTEIN, HUMAN; MAGEA4 PROTEIN, HUMAN; TUMOR ANTIGEN; TUMOR PROTEIN;

ADVANCED CANCER; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; FEVER; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; LUNG CANCER; LUNG METASTASIS; LYMPH NODE METASTASIS; OPEN STUDY; OVERALL SURVIVAL; PROTEIN EXPRESSION; PRURITUS; REGULATORY T LYMPHOCYTE; SKIN REDNESS; STOMACH CANCER; TREATMENT RESPONSE; TUMOR CELL; TUMOR VOLUME; BLOOD; CLINICAL TRIAL; ESOPHAGEAL NEOPLASMS; IMMUNOLOGY; LUNG NEOPLASMS; METABOLISM; PHASE 1 CLINICAL TRIAL; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL RATE;

ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; ESOPHAGEAL NEOPLASMS; HISTOCOMPATIBILITY ANTIGENS CLASS I; IMMUNITY, HUMORAL; INTERFERON-GAMMA; LUNG NEOPLASMS; NANOPARTICLES; NEOPLASM PROTEINS; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL RATE;

EID: 84907967544     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.09.002     Document Type: Article

References (45)

1. Simpson A.J.G., Caballero O.L., Jungbluth A., Chen Y.-T., Old L.J. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005, 5:615-625.
2. Caballero O.L., Chen Y.-T. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci 2009, 100:2014-2021.
3. Nishikawa H., Maeda Y., Ishida T., Gnjatic S., Sato E., Mori F., et al. Cancer/testis antigens are novel targets of immunotherapy for adult T-cell leukemia/lymphoma. Blood 2012, 119:3097-3104.
4. Cesson V., Rivals J.-P., Escher A., Piotet E., Thielemans K., Posevitz V., et al. MAGE-A3 and MAGE-A4 specific CD4(+) T cells in head and neck cancer patients: detection of naturally acquired responses and identification of new epitopes. Cancer Immunol Immunother 2011, 60:23-35.
5. Vansteenkiste J., Zielinski M., Linder A., Dahabreh J., Gonzalez E.E., Malinowski W., et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. J Clin Oncol 2013, 31:2396-2403.
6. Tyagi P., Mirakhur B. MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy. Clin Lung Cancer 2009, 10:371-374.
7. Gnjatic S., Wheeler C., Ebner M., Ritter E., Murray A., Altorki N.K., et al. Seromic analysis of antibody responses in non-small cell lung cancer patients and healthy donors using conformational protein arrays. J Immunol Methods 2009, 341:50-58.
8. Groeper C., Gambazzi F., Zajac P., Bubendorf L., Adamina M., Rosenthal R., et al. Cancer/testis antigen expression and specific cytotoxic T lymphocyte responses in non small cell lung cancer. Int J Cancer 2007, 120:337-343.
9. Kocher T., Zheng M., Bolli M., Simon R., Forster T., Schultz-Thater E., et al. Prognostic relevance of MAGE-A4 tumor antigen expression in transitional cell carcinoma of the urinary bladder: a tissue microarray study. Int J Cancer 2002, 100:702-705.
10. Yakirevich E., Sabo E., Lavie O., Resnick M.B. Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens in serous ovarian neoplasms expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens in serous ovarian neoplasms. Clin Cancer Res 2003, 9:6453-6460.
11. Yoshida N., Abe H., Ohkuri T., Wakita D., Sato M., Noguchi D., et al. Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens and T cell infiltration in non-small cell lung carcinoma and their prognostic significance. Int J Oncol 2006, 28:1089-1098.
12. Bergeron A., Picard V., LaRue H., Harel F., Hovington H., Lacombe L., et al. High frequency of MAGE-A4 and MAGE-A9 expression in high-risk bladder cancer. Int J Cancer 2009, 125:1365-1371.
13. Shigematsu Y., Hanagiri T., Shiota H., Kuroda K., Baba T., Mizukami M., et al. Clinical significance of cancer/testis antigens expression in patients with non-small cell lung cancer. Lung Cancer 2010, 68:105-110.
14. Laban S., Atanackovic D., Luetkens T., Knecht R., Busch C.-J., Freytag M., et al. Simultaneous cytoplasmic and nuclear protein expression of MAGE-A family and NY-ESO-1 cancer-testis antigens represents an independent marker for poor survival in head & neck cancer. Int J Cancer 2014, 135:1-11.
15. Hillig R.C., Coulie P.G., Stroobant V., Saenger W., Ziegler A., Hülsmeyer M. High-resolution structure of HLA-A*0201 in complex with a tumour-specific antigenic peptide encoded by the MAGE-A4 gene. J Mol Biol 2001, 310:1167-1176.
16. Jia Z.-C., Ni B., Huang Z.-M., Tian Y., Tang J., Wang J.-X., et al. Identification of two novel HLA-A*0201-restricted CTL epitopes derived from MAGE-A4. Clin Dev Immunol 2010, 2010:567594.
17. Miyahara Y., Naota H., Wang L., Hiasa A., Goto M., Watanabe M., et al. Determination of cellularly processed HLA-A2402-restricted novel CTL epitopes derived from two cancer germ line genes, MAGE-A4 and SAGE. Clin Cancer Res 2005, 11:5581-5589.
18. Zhang Y., Stroobant V., Russo V., Boon T., van der Bruggen P. A MAGE-A4 peptide presented by HLA-B37 is recognized on human tumors by cytolytic T lymphocytes. Tissue Antigens 2002, 60:365-371.
19. Ohkuri T., Wakita D., Chamoto K., Togashi Y., Kitamura H., Nishimura T. Identification of novel helper epitopes of MAGE-A4 tumour antigen: useful tool for the propagation of Th1 cells. Br J Cancer 2009, 100:1135-1143.
20. Watson N.F.S., Ramage J.M., Madjd Z., Spendlove I., Ellis I.O., Scholefield J.H., et al. Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis. Int J Cancer 2006, 118:6-10.
21. Ishigami S., Natsugoe S., Nakajo A., Arigami T., Kitazono M., Okumura H., et al. HLA-class I expression in gastric cancer. J Surg Oncol 2008, 97:605-608.
22. Simpson J.A.D., Al-Attar A., Watson N.F.S., Scholefield J.H., Ilyas M., Durrant L.G. Intratumoral T cell infiltration, MHC class I and STAT1 as biomarkers of good prognosis in colorectal cancer. Gut 2010, 59:926-933.
23. Hanagiri T., Shigematsu Y., Shinohara S., Takenaka M., Oka S., Chikaishi Y., et al. Clinical significance of expression of cancer/testis antigen and down-regulation of HLA class-I in patients with stage I non-small cell lung cancer. Anticancer Res 2013, 33:2123-2128.
24. Bukur J., Jasinski S., Seliger B. The role of classical and non-classical HLA class I antigens in human tumors. Semin Cancer Biol 2012, 22:350-358.
25. Lampen M.H., van Hall T. Strategies to counteract MHC-I defects in tumors. Curr Opin Immunol 2011, 23:293-298.
26. Cabrera T., Lara E., Romero J.M., Maleno I., Real L.M., Ruiz-Cabello F., et al. HLA class I expression in metastatic melanoma correlates with tumor development during autologous vaccination. Cancer Immunol Immunother 2007, 56:709-717.
27. Carretero R., Romero J.M., Ruiz-Cabello F., Maleno I., Rodriguez F., Camacho F.M., et al. Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy. Immunogenetics 2008, 60:439-447.
28. Gu X.G., Schmitt M., Hiasa A., Nagata Y., Ikeda H., Sasaki Y., et al. A novel hydrophobized polysaccharide/oncoprotein complex vaccine induces in vitro and in vivo cellular and humoral immune responses against HER2-expressing murine sarcomas. Cancer Res 1998, 58:3385-3390.
29. Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247.
30. Trotti A., Colevas A.D., Setser A., Rusch V., Jaques D., Budach V., et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003, 13:176-181.
31. Tanaka H., Miyazaki N., Matoba K., Nogi T., Iwasaki K., Takagi J. Higher-order architecture of cell adhesion mediated by polymorphic synaptic adhesion molecules neurexin and neuroligin. Cell Rep 2012, 2:101-110.
32. Nishikawa H., Sato E., Briones G., Chen L.-M., Matsuo M., Nagata Y., et al. In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines. J Clin Invest 2006, 116:1946-1954.
33. Sugiyama D., Nishikawa H., Maeda Y., Nishioka M., Tanemura A., Katayama I., et al. Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans. Proc Natl Acad Sci U S A 2013, 110:17945-17950.
34. Uenaka A., Wada H., Isobe M., Saika T., Tsuji K., Sato E., et al. T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein. Cancer Immun 2007, 7:9.
35. Kawabata R., Wada H., Isobe M., Saika T., Sato S., Uenaka A., et al. Antibody response against NY-ESO-1 in CHP-NY-ESO-1 vaccinated patients. Int J Cancer 2007, 120:2178-2184.
36. Fujiwara S., Wada H., Kawada J., Kawabata R., Takahashi T., Fujita J., et al. NY-ESO-1 antibody as a novel tumour marker of gastric cancer. Br J Cancer 2013, 108:1119-1125.
37. Kawada J., Wada H., Isobe M., Gnjatic S., Nishikawa H., Jungbluth A.A., et al. Heteroclitic serological response in esophageal and prostate cancer patients after NY-ESO-1 protein vaccination. Int J Cancer 2012, 130:584-592.
38. Tsuji K., Hamada T., Uenaka A., Wada H., Sato E., Isobe M., et al. Induction of immune response against NY-ESO-1 by CHP-NY-ESO-1 vaccination and immune regulation in a melanoma patient. Cancer Immunol Immunother 2008, 57:1429-1437.
39. Wada H., Sato E., Uenaka A., Isobe M., Kawabata R., Nakamura Y., et al. Analysis of peripheral and local anti-tumor immune response in esophageal cancer patients after NY-ESO-1 protein vaccination. Int J Cancer 2008, 123:2362-2369.
40. Kakimi K., Isobe M., Uenaka A., Wada H., Sato E., Doki Y., et al. A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen. Int J Cancer 2011, 129:2836-2846.
41. Wada H., Isobe M., Kakimi K., Mizote Y., Eikawa S., Sato E., et al. Vaccination with NY-ESO-1 overlapping peptides mixed with picibanil OK-432 and montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen. J Immunother 2014, 37:84-92.
42. Schwartzentruber D.J., Lawson D.H., Richards J.M., Conry R.M., Miller D.M., Treisman J., et al. Gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 2011, 364:2119-2127.
43. Kono K., Iinuma H., Akutsu Y., Tanaka H., Hayashi N., Uchikado Y., et al. Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens. J Transl Med 2012, 10:141.
44. Walter S., Weinschenk T., Stenzl A., Zdrojowy R., Pluzanska A., Szczylik C., et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 2012, 18:1254-1261.
45. Corbière V., Chapiro J., Stroobant V., Ma W., Lurquin C., Lethé B., et al. Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases. Cancer Res 2011, 71:1253-1262.